Abstract: Carfilzomib is a second-generation selective proteasome inhibitor that has been recently used for relapse or refractory multiple myeloma（RRMM）. It has been shown to be beneficial in both bortezomib-resistant and bortezomib-naive patients, with a tolerable side effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib.

Key words: Carfilzomib, proteasome inhibitor, multiple myeloma, relapse, refractory, anti-myeloma